Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Mon Oct 21 20:18:51 UTC 2019
by
admin
on
Mon Oct 21 20:18:51 UTC 2019
|
Protein Type | TRANSPORTER |
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
76UB6O122H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ABCG2
Created by
admin on Mon Oct 21 20:18:51 UTC 2019 , Edited by admin on Mon Oct 21 20:18:51 UTC 2019
|
PRIMARY | |||
|
479876-41-0
Created by
admin on Mon Oct 21 20:18:51 UTC 2019 , Edited by admin on Mon Oct 21 20:18:51 UTC 2019
|
PRIMARY | |||
|
481134-43-4
Created by
admin on Mon Oct 21 20:18:51 UTC 2019 , Edited by admin on Mon Oct 21 20:18:51 UTC 2019
|
ALTERNATIVE | |||
|
Q9UNQ0
Created by
admin on Mon Oct 21 20:18:51 UTC 2019 , Edited by admin on Mon Oct 21 20:18:51 UTC 2019
|
PRIMARY | |||
|
481133-43-1
Created by
admin on Mon Oct 21 20:18:51 UTC 2019 , Edited by admin on Mon Oct 21 20:18:51 UTC 2019
|
ALTERNATIVE | |||
|
658014-39-2
Created by
admin on Mon Oct 21 20:18:51 UTC 2019 , Edited by admin on Mon Oct 21 20:18:51 UTC 2019
|
ALTERNATIVE | |||
|
759386-70-4
Created by
admin on Mon Oct 21 20:18:51 UTC 2019 , Edited by admin on Mon Oct 21 20:18:51 UTC 2019
|
ALTERNATIVE |
From | To |
---|---|
1_592 | 1_608 |
2_592 | 2_608 |
3_592 | 3_608 |
4_592 | 4_608 |
1_603 | 2_603 |
3_603 | 4_603 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_596 |
N | 2_596 |
N | 3_596 |
N | 4_596 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TRANSPORTER | |||
|
NON-SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
NON-SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
NON-INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INDUCER -> TRANSPORTER | |||
|
SUBSTRATE -> TARGET | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
NON-SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Regorafenib inhibits Pgp and BCRP in vitro.
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
MINOR
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Netupitnat: Cmax/IC50= (1-1.5μM)/6 μM = (0.167-0.25)>0.1
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Gao et al. reported that in vitro, imatinib (1 ?M) increases the intracellular concentration of vincristine and mitoxantrone in cells overexpressing ABCB1 and ABCG2, respectively (Gao et al., 2006).
CLINICALLY SIGNIFICANT
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Terifluniomide is an inhibitor of BCRP, OAT3, OATP1B1, OCT2 in vitro
|
||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
Niraparib is a substrate of P-gp and BCRP in vitro.
|
||
|
SUBSTRATE -> TRANSPORTER |
In overexpressing BCRP and P-gp cell line, the estimate Km for both transporters is >300 ?M.
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Tafamidis inhibits BCRP in-vitro.
IC50
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
Teriflunomide is a substrate of BCRP in vitro
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
inhibit 6.7% at 10 ?M
IC50
|
||
|
SUBSTRATE -> TRANSPORTER |
Co-administration with BCRP inhibitors may increase talazoparib exposure.
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
NON-SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INDUCER -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
LDV is a substrate for P-gp and BCRP in vitro (AD-256-2144 and AD-256-2150).
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
NON-SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
NON-SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
The clinical relevance of these findings is unknown.
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> METABOLIC ENZYME | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) | CHEMICAL |
|